文献速递心力衰竭与心肌病

非甾体类MRA非奈利酮联合或不联合SGLT2抑制剂在心力衰竭中的效果

Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure.
PubMed 文献 · Circulation · 2024-09-28

FINEARTS-HF试验事后分析纳入6001例LVEF≥40%的心衰患者,其中817例(13.6%)基线使用SGLT2i。非奈利酮对主要复合终点(总恶化心衰事件和心血管死亡)的降低风险在联合或不联合SGLT2i者中一致,提示联合治疗可能提供叠加保护。

要点

  • 非奈利酮在LVEF≥40%心衰患者中的获益不受基线是否使用SGLT2i影响。
  • 联合使用SGLT2i与非奈利酮可能对心血管事件提供叠加保护。
  • 非奈利酮组随访期间新启动SGLT2i的比例低于安慰剂组。

核心结论

  • 非奈利酮的治疗获益在联合或不联合SGLT2i使用时均观察到。
  • SGLT2i与非甾体类MRA联合使用可能对射血分数轻度降低或保留的心衰患者提供叠加的心血管事件保护。

研究设计与样本

  • FINEARTS-HF为随机、双盲、安慰剂对照试验,纳入左心室射血分数≥40%的心衰患者。
  • 共6001例参与者,其中817例(13.6%)基线使用SGLT2i。
  • 基线SGLT2i使用为预设亚组,中位随访2.6年。

主要发现

  • 非奈利酮对主要终点(总恶化心衰事件和心血管死亡)的风险比在基线使用SGLT2i者为0.83(95%CI 0.60-1.16),未使用者为0.85(95%CI 0.74-0.98),交互作用P=0.76。
  • 随访期间980例启动SGLT2i,非奈利酮组启动比例低于安慰剂组(17.7% vs 20.1%;HR 0.86,95%CI 0.76-0.97)。
  • 考虑基线和随访期间SGLT2i使用的时间更新分析未实质性改变非奈利酮对主要终点的治疗效果。

临床怎么用

  • 对于LVEF≥40%的心衰患者,非奈利酮的获益不受是否联合SGLT2i影响,可考虑联合使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with heart failure (HF) with mildly reduced or preserved ejection fraction face heightened long-term risks of morbidity and mortality. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and the nonsteroidal mineralocorticoid receptor antagonist finerenone have both been shown to reduce the risk of cardiovascular events in this population, but the effects of their combined use are not known. METHODS: FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure) was a randomized, double-blind, placebo-controlled trial of finerenone in patients with HF and left ventricular ejection fraction ≥40%. Baseline SGLT2i use was a prespecified subgroup. The primary outcome was a composite of total (first and recurrent) worsening HF events and cardiovascular death. We first assessed for evidence of treatment heterogeneity on the basis of baseline SGLT2i use. We further examined SGLT2i uptake during the trial and evaluated the treatment effects of finerenone accounting for baseline and during-trial use of SGLT2i in time-varying analyses. RESULTS: Among 6001 participants, 817 (13.6%) were treated with an SGLT2i at baseline. During 2.6 years median follow-up, treatment with finerenone similarly reduced the risk of the primary outcome in participants treated with an SGLT2i (rate ratio, 0.83 [95% CI, 0.60-1.16]) and without an SGLT2i at baseline (rate ratio, 0.85 [95% CI, 0.74-0.98]; Pinteraction=0.76). In follow-up, 980 participants initiated SGLT2i, which was less frequent in the finerenone arm compared with placebo (17.7% versus 20.1%; hazard ratio, 0.86 [95% CI, 0.76-0.97]). Time-updated analyses accounting for baseline and subsequent use of SGLT2i did not meaningfully alter the treatment effects of finerenone on the primary end point. CONCLUSIONS: The treatment benefits of the nonsteroidal mineralocorticoid receptor antagonist finerenone were observed irrespective of concomitant use of an SGLT2i. These data suggest that the combined use of SGLT2i and a nonsteroidal mineralocorticoid receptor antagonist may provide additive protection against cardiovascular events in patients with HF with mildly reduced or preserved ejection fraction. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04435626.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Vaduganathan, Claggett, Kulac, et al. Effects of the Nonsteroidal MRA Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 2024. PMID: 39340828. doi:10.1161/CIRCULATIONAHA.124.072055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。